The Patent Finder

Synthetic Membrane-Receiver Complexes

Rubius Therapeutics, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 5 of these applications claim priority to application 14/738,414, filed Jun 12, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 10,253,296Synthetic Membrane-Receiver Complexes
In force
 · Medium confidence
UsedRemaining
Rubius Therapeutics, Inc.In forceMedium confidence
US 10,301,593Synthetic Membrane-Receiver Complexes
In force
 · Medium confidence
Rubius Therapeutics, Inc.In forceMedium confidence
US 10,301,594Synthetic Membrane-Receiver Complexes
In force
 · High confidence
Rubius Therapeutics, Inc.In forceHigh confidence
US 10,329,531Synthetic Membrane-Receiver Complexes
In force
 · High confidence
Rubius Therapeutics, Inc.In forceHigh confidence
US 10,344,263Synthetic Membrane-Receiver Complexes
In force
 · High confidence
Rubius Therapeutics, Inc.In forceHigh confidence
US 10,557,119Erythroid Cells Comprising Phenylalanine Ammonia Lyase
Lapsed Feb 11, 2024 on the fee record
Medium confidence
Rubius Therapeutics, Inc.Lapsed Feb 11, 2024 on the fee recordMedium confidence
US 9,644,180Synthetic Membrane-Receiver Complexes
Lapsed May 9, 2025 on the fee record
Medium confidence
Rubius Therapeutics, Inc.Lapsed May 9, 2025 on the fee recordMedium confidence
Application 14/581,486Synthetic Membrane-Receiver Complexes
Abandoned
Abandoned Feb 14, 2017
Rubius Therapeutics, Inc.AbandonedAbandoned Feb 14, 2017
Application 15/157,006Genetically Engineered Enucleated Erythroid Cells Comprising a Phenylalanine Ammonia Lyase Receiver Polypeptide
Abandoned
Abandoned Jan 22, 2019
Rubius Therapeutics, Inc.AbandonedAbandoned Jan 22, 2019
Application 15/899,895Erythroid Cells Comprising Uricase
Abandoned
Abandoned Jun 17, 2022
Rubius Therapeutics, Inc.AbandonedAbandoned Jun 17, 2022
10 more records in this group · Pro
10 of 20 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 20, including 2 expired.
Upgrade to Pro
5 of these are in force and held by Rubius Therapeutics, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited